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Spectral analysisAbstract Heterocyclic molecules belong to the most attractive group owing to their broad spectrum
of antimicrobial activities. In the undertaken research, a number of new 5-substituted-2-((6-chloro-
3,4-methylenedioxyphenyl)methylthio)-1,3,4-Oxadiazole derivatives (6a–l) were synthesized by con-
verting various aryl/aralkyl carboxylic acids (1a–l) into corresponding esters (2a–l), carbohydrazides
(3a–l) and 5-substituted-1,3,4-Oxadiazol-2-thiols (4a–l). The last step included the synthesis of target
molecules, 6a–l, by stirring 4a–l and 6-chloro-3,4-methylenedioxybenzyl chloride (5) in a polar aprotic
solvent. The structures of all the synthesized molecules were corroborated through spectral analysis.
The screening of these molecules against antibacterial activity rendered themmoderate inhibitors and
most likely against Escherichia coli, relative to the reference standard, ciproﬂoxacin.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Heterocyclic molecules such as Oxadiazoles have been synthe-
sized and evaluated for medical and agricultural activities. The
disubstituted Oxadiazoles have executed a range of pharmaco-
logic activities. 1,3,4-Oxadiazole heterocycle has displayedmany activities like antibacterial, antifungal, hypoglycemic
and anti-inﬂammatory. It also possesses an important place
in medicinal chemistry. Chemists are much interested in
2,5-disubstituted 1,3,4-Oxadiazoles because of their antimicro-
bial activities.1–6 The heterocycle, 3,4-methylenedioxyphenyl
ring is also the part of active drugs. The molecules employed
as antitumor and anticancer possessing this ring are lycorici-
dine, narciclasine and pancratistatin.7 Moreover, the antide-
pressant drugs such as paroxetine also bear this moiety.8
The structural modiﬁcation leads to variation in antimicro-
bial activities of the molecules. This prompted us to extend our
previous work9–11 to synthesize 5-substituted-2-((6-chloro-3,
38 Aziz-ur-Rehman et al.4-methylenedioxyphenyl)methylthio)-1,3,4-Oxadiazole deriva-
tives with an aim to observe their antibacterial activity. The
synthesized molecules were found to be better inhibitors of
Escherichia coli and Pseudomonas aeroginosa relative to
ciproﬂoxacin.
2. Materials and methods
2.1. General
The reagents, purchased from Alfa Aesar and Sigma–Aldrich,
were of synthetic grade and the solvents, obtained through
commercial suppliers, were of analytical grade. Melting points
of the synthesized molecules were measured on Grifﬁn-George
apparatus in an open capillary tube and were uncorrected. Pur-
ity and reaction progress were monitored through thin layer
chromatography (TLC) on coated silica gel G-25-UV254 plates
using different ratios of ethyl acetate and n-hexane as solvent
systems. KBr (potassium bromide) pellet procedure was used
to record I.R. spectra on a Jasco-320-A spectrophotometer.
Wave number is given in cm1. Bruker spectrometers are
employed for 1H NMR & 13C NMR spectra in CDCl3 at
400–100 MHz. Chemical shifts are given in ppm relative to
TMS and coupling constant in Hz. EIMS were recorded
through JMS-HX-110 spectrometer, with a data system.
2.2. General procedure for the synthesis of esters (2a–l)
The aryl/aralkyl carboxylic acids (1a–l; 2.0 g) were dissolved in
8.0 mL absolute ethanol followed by the addition of 1.0 mL
concentrated sulfuric acid in a 100 mL round bottom (RB)
ﬂask. The mixture was reﬂuxed for 2–5 h. After reaction
completion, established by TLC (ethyl acetate:n-hexane,
20%:80%), the mixture was poured into a 250 mL separating
funnel. Then 80 mL distilled water and concentrated aqueous
sodium carbonate solution were added to set a pH 9,10. The
solvent, 30 mL diethyl ether was added and upper ether layer
containing required ester was collected after shaking. The sol-
vent was distilled off to afford the transparent esters, 2a–l, with
yields ranging 62–76%.9–102.3. General procedure for the synthesis of hydrazides (3a–l)
The esters (2a–l; 0.02 mol) were added to 20.0 mL ethanol in a
100 mL RB ﬂask followed by 4.0 mL 80% hydrazine hydrate.
The mixture was stirred or reﬂuxed accordingly for 3–6 h till
reaction completion, supervised by TLC (ethyl acetate:n-
hexane, 40%:60%). The precipitates of solid products were
generated after addition of excess of distilled water which were
ﬁltered and washed with distilled water to afford 3a–l, with
yields ranging 71–87%.9,10
2.4. General procedure for the synthesis of 5-substituted-1,3,4-
Oxadiazol-2-thiols (4a–l)
The carbohydrazides (3a–l; 0.02 mol) were suspended in
20.0 mL absolute ethanol in a 100 mL RB ﬂask, basiﬁed with
potassium hydroxide (0.02 mol) and reﬂuxed to homogenize
the mixture. Carbon disulﬁde (0.04 mol) was poured to themixture and reﬂuxed it for 4–6 h. TLC (ethyl acetate:n-hexane,
30%:70%) was developed to verify the reaction completion.
The mixture was diluted by 30–50 mL distilled water and dilute
HCl was added to acidify up to pH = 3–4. The precipitates,
4a–l, were collected through ﬁltration and washed by distilled
water. The compounds were obtained with yields ranging
74–81%.9,10
2.5. General procedure for the synthesis of 5-substituted-2-((6-
chloro-3,4-methylenedioxyphenyl)methylthio)-1,3,4-Oxadiazole
(6a–l)
5-substituted-1,3,4-Oxadiazol-2-thiols (4a–l; 0.2 mmol) were
homogeneously dissolved in 15.0 mL N,N-dimethylformamide
(DMF) in a 50 mL RB ﬂask. After activation of 4a–l by
sodium hydride (0.2 mmol) on stirring for half an hour,
6-chloro-3,4-methylenedioxybenzyl chloride (5; 0.2 mmol)
was added and further stirred for 3–5 h. After complete reac-
tion, monitored through TLC (ethyl acetate:n-hexane,
30%:70%), cold distilled water was added and the products
were isolated by ﬁltration or solvent extraction. The ﬁnal solid
products were re-crystallized from methanol.
2.5.1. 5-Phenyl-2-((6-chloro-3,4-
methylenedioxyphenyl)methylthio)-1,3,4-Oxadiazole (6a)
White amorphous solid; Yield: 99%; M.P: 155 C; HR-MS:
[M]+ 346.0176 (Calcd. for C16H11ClN2O3S; 346.0183); IR
(KBr): vmax (cm
1): 3053 (ArAH stretching), 1533 (Ar C‚C
stretching), 1125 (CAO stretching), 711 (CACl stretching),
610 (CAS stretching); 1H NMR (CDCl3, 400 MHz, d/ppm):
7.98 (dd, J= 8.0, 1.2 Hz, 2H, H-200 & 600), 7.50–7.45 (m, 3H,
H-300 to 500), 7.09 (s, 1H, H-20), 6.84 (s, 1H, H-50), 5.94 (s,
2H, H-70), 4.53 (s, 2H, H-80); 13C NMR (CDCl3, 100 MHz,
d/ppm): 165.4 (C-5), 164.6 (C-2), 150.3 (C-40), 148.7 (C-30),
135.2 (C-300 & 500), 132.8 (C-200 & 600), 130.4 (C-400), 129.8 (C-
100), 129.5 (C-10), 125.7 (C-60), 110.9 (C-50), 110.2 (C-20),
101.9 (C-70), 32.7 (C-80); EIMS (m/z): 348 [M+2]+ (0.3%),
346 [M]+ (1%), 311 (100%), 200 (2%), 178 (2%), 169 (8%),
145 (12%), 139 (4%), 134 (3%), 119 (7%), 105 (8%), 104
(4%), 103 (5%), 77 (9%), 51 (3%).
2.5.2. 5-(2-Methylphenyl)-2-((6-chloro-3,4-
methylenedioxyphenyl)methylthio)-1,3,4-Oxadiazole (6b)
White amorphous solid; Yield: 90%; M.P: 109 C; HR-MS:
[M]+ 360.0332 (Calcd. for C17H13ClN2O3S; 360.0341); IR
(KBr): vmax (cm
1): 3058 (ArAH stretching), 1539 (Ar C‚C
stretching), 1121 (CAO stretching), 707 (CACl stretching),
617 (CAS stretching); 1H NMR (CDCl3, 400 MHz, d/ppm):
7.84 (d, J= 7.6 Hz, 1H, H-600), 7.40 (t, J= 7.2 Hz,1H, H-
400), 7.32 (d, J= 7.6 Hz, 1H, H-300), 7.28 (t, J= 7.6 Hz, 1H,
H-500), 7.12 (s, 1H, H-20), 6.85 (s, 1H, H-50), 5.95 (s, 2H, H-
70), 4.53 (s, 2H, H-80), 2.67 (s, 3H, H-700); 13C NMR (CDCl3,
100 MHz, d/ppm): 164.8 (C-5), 164.1 (C-2), 150.1 (C-40),
149.4 (C-30), 134.3 (C-200), 131.6 (C-10), 130.9 (C-400), 128.8
(C-300), 128.1 (C-100), 127.6 (C-500), 126.8 (C-60), 126.2 (C-600),
111.2 (C-50), 110.6 (C-20), 101.8 (C-70), 32.5 (C-80), 20.1 (C-
700); EIMS (m/z): 362 [M+2]+ (0.5%), 360 [M]+ (1.5%), 325
(100%), 200 (2%), 192 (5%), 169 (8%), 160 (2%), 139 (8%),
134 (3%), 133 (6%), 119 (4%), 117 (3%), 104 (9%), 91
(30%), 51 (2%).
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phenyl)methylthio)-1,3,4-Oxadiazole (6c)
White amorphous solid; Yield: 96%; M.P: 198 C; HR-MS:
[M]+ 360.0332 (Calcd. for C17H13ClN2O3S; 360.0341); IR
(KBr): vmax (cm
1): 3047 (ArAH stretching), 1536 (Ar C‚C
stretching), 1118 (CAO stretching), 705 (CACl stretching),
617 (CAS stretching); 1H NMR (CDCl3, 400 MHz, d/ppm):
7.86 (d, J= 8.0 Hz, 2H, H-200 & 600), 7.20 (d, J= 8.4 Hz, 2H,
H-300 & 500), 7.09 (s, 1H, H-20), 6.84 (s, 1H, H-50), 5.94 (s, 2H,
H-70), 4.52 (s, 2H, H-80), 2.40 (s, 3H, H-700); 13C NMR (CDCl3,
100 MHz, d/ppm): 165.7 (C-5), 164.4 (C-2), 149.8 (C-40), 149.2
(C-30), 140.4 (C-400), 130.9 (C-10), 130.2 (C-200 & 600), 129.7 (C-
100), 129.1 (C-300 & 500), 125.6 (C-60), 110.5 (C-50), 110.0 (C-20),
101.6 (C-70), 32.9 (C-80), 20.9 (C-700); EIMS (m/z): 362
[M+2]+ (0.3%), 360 [M]+ (1%), 325 (100%), 200 (3%), 192
(4%), 169 (7%), 160 (3%), 139 (6%), 134 (4%), 133 (5%), 119
(6%), 117 (2%), 104 (7%), 91 (23%), 51 (6%).
2.5.4. 5-(2-Nitrophenyl)-2-((6-chloro-3,4-methylenedioxy
phenyl)methylthio)-1,3,4-Oxadiazole (6d)
White amorphous solid; Yield: 97%; M.P: 125 C; HR-MS:
[M]+ 391.0031 (Calcd. For C16H10ClN3O5S; 391.0037); IR
(KBr): vmax (cm
1): 3061 (ArAH stretching), 1542 (Ar C‚C
stretching), 1258 (CAN stretching), 1133 (CAO stretching),
710 (CACl stretching), 619 (CAS stretching); 1H NMR
(CDCl3, 400 MHz, d/ppm): 8.01 (dd, J= 9.2, 1.6 Hz, 1H, H-
300), 7.92 (dd, J= 8.8, 1.6 Hz, 1H, H-600), 7.74 (dt, J= 9.2,
2.0 Hz,1H, H-400), 6.74 (t, J= 7.6 Hz, 1H, H-500), 7.02 (s,
1H, H-20), 6.85 (s, 1H, H-50), 5.96 (s, 2H, H-70), 4.52 (s, 2H,
H-80); 13C NMR (CDCl3, 100 MHz, d/ppm): 165.1 (C-2),
164.2 (C-5), 150.4 (C-40), 149.7 (C-30), 146.2 (C-200), 132.5 (C-
400), 130.8 (C-500), 130.1 (C-10), 127.9 (C-300), 126.8 (C-60),
126.2 (C-600), 124.7 (C-100), 110.9 (C-50), 110.3 (C-20), 101.5
(C-70), 31.8 (C-80); EIMS (m/z): 393 [M+2]+ (0.3%), 391
[M]+ (1%), 356 (25%), 222 (100%), 200 (4%), 192 (7%),
190 (5%), 169 (9%), 164 (90%), 150 (2%), 148 (5%), 139
(2%), 134 (3%), 122 (7%), 104 (3%), 51 (3%).
2.5.5. 5-(3-Nitrophenyl)-2-((6-chloro-3,4-methylenedioxy
phenyl)methylthio)-1,3,4-Oxadiazole (6e)
Creamy white amorphous solid; Yield: 99%; M.P: 200 C; HR-
MS: [M]+ 391.0031 (Calcd. For C16H10ClN3O5S; 391.0037); IR
(KBr): vmax (cm
1): 3065 (ArAH stretching), 1543 (Ar C‚C
stretching), 1253 (CAN stretching), 1134 (CAO stretching),
708 (CACl stretching), 616 (CAS stretching); 1HNMR (CDCl3,
400 MHz, d/ppm): 8.35 (d, J = 8.0 Hz, 1H, H-400), 8.17 (d,
J = 7.6 Hz, 1H, H-600), 7.99 (s, 1H, H-200), 7.92–7.90 (m,1H,
H-500), 7.13 (s, 1H, H-20), 7.02 (s, 1H, H-50), 5.95 (s, 2H, H-70),
4.58 (s, 2H, H-80); 13C NMR (CDCl3, 100 MHz, d/ppm): 165.4
(C-5), 164.6 (C-2), 150.7 (C-40), 150.0 (C-30), 149.2 (C-300),
136.3 (C-600), 132.5 (C-100), 131.2 (C-500), 129.8 (C-10), 126.3 (C-
60), 125.1 (C-400), 122.6 (C-200), 110.8 (C-50), 110.0 (C-20), 101.1
(C-70), 32.4 (C-80); EIMS (m/z): 393 [M+2]+ (0.3%), 391
[M]+ (1%), 356 (25%), 222 (100%), 200 (4%), 192 (7%), 190
(5%), 169 (9%), 164 (90%), 150 (2%), 148 (5%), 139 (2%),
134 (3%), 122 (7%), 104 (3%), 51 (3%).
2.5.6. 5-(2-Chlorophenyl)-2-((6-chloro-3,4-methylenedioxy
phenyl)methylthio)-1,3,4-Oxadiazole (6f)
White amorphous solid; Yield: 98%; M.P: 160 C; HR-MS:
[M]+ 379.9784 (Calcd. For C16H10Cl2N2O3S; 379.9793); IR(KBr): vmax (cm
1): 3055 (ArAH stretching), 1536 (Ar C‚C
stretching), 1127 (CAO stretching), 713 (CACl stretching),
614 (CAS stretching); 1H NMR (CDCl3, 400 MHz, d/ppm):
7.91 (dd, J= 8.0, 1.6 Hz, 1H, H-300), 7.53 (dd, J= 8.0,
1.6 Hz, 1H, H-600), 7.45 (dt, J= 7.6, 1.2 Hz, 1H, H-400), 7.38
(dt, J= 7.6, 1.6 Hz, 1H, H-500), 7.11 (s, 1H, H-20), 6.85 (s,
1H, H-50), 5.95 (s, 2H, H-70), 4.55 (s, 2H, H-80); 13C NMR
(CDCl3, 100 MHz, d/ppm): 167.3 (C-5), 165.3 (C-2), 150.7
(C-40), 149.9 (C-30), 132.8 (C-400), 131.1 (C-200), 130.7 (C-10),
128.4 (C-300), 126.7 (C-600), 125.7 (C-500), 124.3 (C-100), 123.5
(C-60), 110.8 (C-50), 110.4 (C-20), 101.4 (C-70), 31.9 (C-80);
EIMS (m/z): 384 [M+4]+ (0.3%), 382 [M+2]+ (0.7%), 380
[M]+ (1%), 345 (100%), 212 (3%), 200 (2%), 179 (16%),
169 (9%), 153 (85%), 139 (6%), 137 (5%), 134 (2%), 111
(8%), 104 (6%), 51 (3%).
2.5.7. 5-(4-Hydroxyphenyl)-2-((6-chloro-3,4-methylenedioxy
phenyl)methylthio)-1,3,4-Oxadiazole (6g)
White amorphous solid; Yield: 98%; M.P: 145 C; HR-MS:
[M]+ 362.0126 (Calcd. For C16H11ClN2O4S; 362.0136); IR
(KBr): vmax (cm
1): 3216 (OAH stretching), 3060 (ArAH
stretching), 1537 (Ar CAC stretching), 1119 (CAO stretching),
703 (CACl stretching), 618 (CAS stretching); 1H NMR
(CDCl3, 400 MHz, d/ppm): 7.88 (d, J= 8.4 Hz, 2H, H-200 &
600), 7.12 (s, 1H, H-20), 6.91 (d, J= 8.8 Hz, 2H, H-300 & 500),
6.84 (s, 1H, H-50), 5.94 (s, 2H, H-70), 4.51 (s, 2H, H-80); 13C
NMR (CDCl3, 100 MHz, d/ppm): 164.9 (C-5), 164.1 (C-2),
159.7 (C-400), 150.0 (C-40), 148.6 (C-30), 130.6 (C-10), 125.3
(C-60), 124.4 (C-100), 123.2 (C-200 & 600), 119.1 (C-300 & 500),
110.8 (C-50), 110.1 (C-20), 101.5 (C-70), 32.7 (C-80); EIMS (m/
z): 364 [M+2]+ (0.3%), 362 [M]+ (1.5%), 327 (100%), 200
(2%), 194 (5%), 169 (9%), 161 (2%), 139 (4%), 135 (9%),
134 (20%), 121 (8%), 119 (6%), 104 (7%), 93 (15%), 51 (4%).
2.5.8. 5-(4-Methoxyphenyl)-2-((6-chloro-3,4-methylenedioxy
phenyl)methylthio)-1,3,4-Oxadiazole (6h)
White amorphous solid; Yield: 98%; M.P: 150 C; HR-MS:
[M]+ 376.0283 (Calcd. For C17H13ClN2O4S; 376.0292); IR
(KBr): vmax (cm
1): 3047 (ArAH stretching), 1536 (Ar C‚C
stretching), 1139 (CAO stretching), 704 (CACl stretching),
613 (CAS stretching); 1H NMR (CDCl3, 400 MHz, d/ppm):
7.91 (d, J= 8.8 Hz, 2H, H-200 & 600), 7.08 (s, 1H, H-50), 6.98
(d, J= 8.8 Hz, 2H, H-300 & 500), 6.84 (s, 1H, H-20), 5.94 (s,
2H, H-70), 4.51 (s, 2H, H-80), 3.85 (s, 3H, H-700); 13C NMR
(CDCl3, 100 MHz, d/ppm): 164.6 (C-5), 163.8 (C-2), 158.2
(C-400), 150.3 (C-40), 149.7 (C-30), 130.3 (C-10), 125.7 (C-60),
124.1 (C-100), 117.4 (C-200 & 600), 116.7 (C-300 & 500), 110.8 (C-
50), 110.2 (C-20), 101.6 (C-70), 58.2 (C-700), 32.4 (C-80); EIMS
(m/z): 378 [M+2]+ (0.3%), 376 [M]+ (1%), 341 (100%), 208
(16%), 200 (2%), 175 (7%), 169 (9%), 149 (2%), 139 (4%),
133 (6%), 134 (3%), 135 (4%), 107 (3%), 104 (9%), 51 (2%).
2.5.9. 5-(2-(3,4-Methylenedioxyphenyl)ethenyl)-2-((6-chloro-
3,4-methylenedioxy phenyl)methylthio)-1,3,4-Oxadiazole (6i)
Gray amorphous solid; Yield: 98%; M.P: 116 C; HR-MS:
[M]+ 416.0235 (Calcd. For C19H13ClN2O5S; 416.0255); IR
(KBr): vmax (cm
1): 3063 (Ar-H stretching), 1654 (C‚C
stretching), 1543 (Ar C‚C stretching), 1135 (CAO stretching),
701 (CACl stretching), 621 (CAS stretching); 1H NMR
(CDCl3, 400 MHz, d/ppm): 7.35 (d, J = 16.4 Hz, 1H, H-900),
7.06 (s, 1H, H-50), 7.02 (d, J= 1.6 Hz, 1H, H-200), 6.98 (dd,
40 Aziz-ur-Rehman et al.J= 8.0, 1.2 Hz, 1H, H-600), 6.84 (s, 1H, H-20), 6.81 (d,
J= 8.0 Hz, 1H, H-500), 6.79 (d, J= 16.4 Hz, 1H, H-800), 5.99
(s, 2H, H-700), 5.94 (s, 2H, H-70), 4.50 (s, 2H, H-80); 13C
NMR (CDCl3, 100 MHz, d/ppm): 165.3 (C-2), 164.8 (C-5),
150.8 (C-400), 150.4 (C-40), 149.3 (C-30), 148.9 (C-300), 140.5
(C-800), 131.2 (C-100), 130.7 (C-10), 125.1 (C-60), 121.3 (C-600),
110.7 (C-50), 110.3 (C-20), 108.6 (C-900), 107.8 (C-500), 107.2
(C-200), 101.7 (C-70), 101.3 (C-700), 32.4 (C-80); EIMS (m/z):
418 [M+2]+ (0.3%), 416 [M]+ (1%), 381 (100%), 248 (8%),
215 (100%), 200 (7%), 189 (3%), 175 (2%), 173 (2%), 169
(7%), 147 (4%), 139 (4%), 134 (3%), 121 (7%), 104 (9%),
91 (13%), 51 (2%).
2.5.10. 5-(4-Chlorophenoxymethyl)-2-((6-chloro-3,4-methyl
enedioxyphenyl)methyl thio)-1,3,4-Oxadiazole (6j)
White amorphous solid; Yield: 98%; M.P: 96 C; HR-MS:
[M]+ 409.9891 (Calcd. For C17H12Cl2N2O4S; 409.9894); IR
(KBr): vmax (cm
1): 3056 (ArAH stretching), 1649 (C‚C
stretching), 1540 (Ar C‚C stretching), 1131 (CAO stretching),
705 (CACl stretching), 617 (CAS stretching); 1H NMR
(CDCl3, 400 MHz, d/ppm): 7.25 (d, J= 8.8 Hz, 2H, H-300 &
500), 7.06 (s, 1H, H-20), 6.92 (d, J= 8.8 Hz, 2H, H-200 & 600),
6.83 (s, 1H, H-50), 5.95 (s, 2H, H-70), 5.16 (s, 2H, H-700), 4.49
(s, 2H, H-80); 13C NMR (CDCl3, 100 MHz, d/ppm): 165.6
(C-2), 164.4 (C-5), 153.7 (C-100), 149.5 (C-40), 148.1 (C-30),
142.4 (C-400), 130.8 (C-10), 127.6 (C-300 & 500), 125.5 (C-60),
113.6 (C-200 & 600), 110.9 (C-50), 110.3 (C-20), 101.8 (C-70),
65.7 (C-700), 32.4 (C-80); EIMS (m/z): 414 [M+4]+ (0.5%),
412 [M+2]+ (1.2%), 410 [M]+ (1.5%), 375 (100%), 242
(1%), 209 (1%), 200 (2%), 183 (2%), 169 (9%), 167 (6%),
141 (2%), 139 (2%), 134 (2%), 111 (15%), 104 (5%), 76
(63%), 51 (3%).
2.5.11. 5-(Naphthalen-1-ylmethyl)-2-((6-chloro-3,4-methyl
enedioxyphenyl)methyl thio)-1,3,4-Oxadiazole (6k)
White amorphous solid; Yield: 99%; M.P: 98 C; HR-MS:
[M]+ 410.0496 (Calcd. For C21H15ClN2O3S; 410.0499); IR
(KBr): vmax (cm
1): 3051 (ArAH stretching), 1537 (Ar C‚C
stretching), 1126 (CAO stretching), 703 (CACl stretching),
613 (CAS stretching); 1H NMR (CDCl3, 400 MHz, d/ppm):
8.09 (d, J= 8.4 Hz, 1H, H-400), 7.86 (d, J= 8.0 Hz, 1H, H-
800), 7.81 (dd, J= 7.2, 2.0 Hz, 1H, H-500), 7.54 (t, J= 7.2,
Hz, 1H, H-700), 7.51 (t, J= 8.0 Hz, 1H, H-600), 7.44–7.41 (m,
2H, H-200 & 300), 6.93 (s, 1H, H-20), 6.77 (s, 1H, H-50), 5.92
(s, 2H, H-70), 4.58 (s, 2H, H-1100), 4.37 (s, 2H, H-80); 13C
NMR (CDCl3, 100 MHz, d/ppm): 165.9 (C-5), 164.6 (C-2),
149.9 (C-40), 148.4 (C-30), 141.7 (C-100), 131.2 (C-500), 130.6
(C-10), 130.1 (C-400), 129.7 (C-1000), 128.1 (C-700), 127.4 (C-600),
126.8 (C-300), 125.3 (C-60), 125.1 (C-200), 123.9 (C-800), 120.5
(C-900), 110.8 (C-50), 110.1 (C-20), 101.4 (C-70), 34.2 (C-1100),
32.7 (C-80); EIMS (m/z): 412 [M+2]+ (0.3%), 410 [M]+
(1%), 375 (100%), 242 (4%), 209 (5%), 200 (2%), 183 (3%),
169 (9%), 167 (7%), 141 (4%), 139 (3%), 134 (1%), 127
(8%), 104 (2%), 101 (3%).
2.5.12. 5-[1-(Phenylsulfonyl)piperidyl]-2-((6-chloro-3,4-
methylenedioxyphenyl) methylthio)-1,3,4-oxadiazole (6l)
White amorphous solid; Yield: 95%; M.P: 130 C; HR-MS:
[M]+ 493.0537 (Calcd. For C21H20ClN3O5S2; 493.0557); IR
(KBr): vmax (cm
1): 3047 (ArAH stretching), 1529 (Ar C‚C
stretching), 1407 (S‚O stretching), 1123 (CAO stretching),712 (CACl stretching), 615 (CAS stretching); 1H NMR
(CDCl3, 400 MHz, d/ppm): 7.76 (d, J= 7.6 Hz, 2H, H-2000 &
6000), 7.59 (t, J= 7.6, 1H, H-4000), 7.54 (t, J= 7.6 Hz, 2H,
H-3000 & 5000), 7.00 (s, 1H, H-20), 6.82 (s, 1H, H-50), 5.94 (s,
2H, H-70), 4.42 (s, 2H, H-80), 3.70 (dt, J= 7.6, 4.0 Hz, 2H,
Heq-2
00 & 600), 2.82–2.79 (m, 1H, H-400), 2.57 (dt, J= 6.8,
2.0 Hz, 2H, Hax-2
00 & 600), 2.11 (dd, J= 13.5, 3.0 Hz, 2H,
Heq-3
00 & 500), 1.98 (dq, J= 11.0, 4.0 Hz, 2H, Hax-300 & 500);
13C NMR (CDCl3, 100 MHz, d/ppm): 170.7 (C-5), 164.7 (C-
2), 149.9 (C-40), 148.3 (C-30), 144.8 (C-1000), 133.5 (C-4000),
130.4 (C-10), 129.3 (C-3000 & 5000), 128.4 (C-2000 & 6000), 125.7
(C-60), 110.7 (C-50), 110.0 (C-20), 101.5 (C-70), 41.5 (C-200 &
600), 35.1 (C-400), 32.7 (C-80), 29.6 (C-300 & 500); EIMS (m/z):
495 [M+2]+ (0.3%), 493 [M]+ (1%), 458 (100%), 394 (1%),
325 (2%), 224 (7%), 200 (3%), 183 (3%), 169 (4%), 141
(9%), 139 (2%), 134 (2%), 104 (8%), 77 (10%), 51 (2%).
2.6. Antibacterial activity
The antibacterial activity of all the synthesized molecules was
calculated by the reported method.12–14
2.7. Statistical analysis
Statistical analysis was accomplished by Microsoft Excel 2010
for all the measurements achieved in triplicate (threefold) and
the results are presented as mean±sem.
3. Results and discussion
The S-substituted derivatives of 5-substituted-1,3,4-Oxadiazol-
2-thiol have been synthesized by the protocol outlined in
Scheme 1. The synthesized 5-substituted-2-((6-chloro-3,
4-methylenedioxyphenyl)methylthio)-1,3,4-Oxadiazole deriva-
tives, 6a–l, were evaluated for antibacterial activity. The step-
wise procedures, conditions and spectral characterization are
explicated in experimental section.
3.1. Chemistry
We synthesized 5-substituted-2-((6-chloro-3,4-methylenedi-
oxyphenyl)methylthio)-1,3,4-Oxadiazole derivatives in good
to excellent yields with moderate antibacterial activities. These
molecules were geared up by the stepwise synthesis involving
esteriﬁcation of aryl/aralkyl carboxylic acids (1a–l) into ethyl
esters (2a–l) by reﬂuxing with ethanol and small amount of
sulfuric acid, nucleophilic substitution of 2a–l by hydrazine
into corresponding carbohydrazides (3a–l) by stirring, the
intermolecular cyclization of 3a–l to 5-substituted-1,3,4-Oxa-
diazol-2-thiols (4a–l) by reﬂuxing with CS2/KOH in ethanol
and ﬁnally the electrophilic substitution of 4a–l by 6-chloro-
3,4-methylenedioxybenzyl chloride (5) in DMF and NaH
(Scheme 1). The purported structures of all the molecules were
conﬁrmed by the spectral data, elaborated in experimental
section.
White amorphous solid, compound 6a, was synthesized in a
good yield of 99% with 155 C melting point. Molecular for-
mula, C16H11ClN2O3S was checked out by molecular ion peak
at m/z 346 & [M+2]+ ion peak at m/z 348 in EI-MS and by
integration curve of protons in 1H NMR spectrum. The IR
spectrum supported the structure by different absorption
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Scheme 1 Synthesis of 5-substituted-2-((6-chloro-3,4-methylenedioxyphenyl)methylthio)-1,3,4-Oxadiazole.
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1051–1079 cm1 for CAO (stretching) in all the molecules
afﬁrming the 1,3,4-Oxadiazole ring. In the EI-MS, a base peak
was noted at m/z 311 after the removal of chlorine radical from
the molecule. The prominent peaks appeared at m/z 178 for
5-phenyl-1,3,4-Oxadiazol-2-thiol cation and at m/z 169 for
6-chloro-3,4-methylenedioxyphenyl)methyl cation. For more
details, the mass fragmentation pattern of 5-phenyl-2-((6-
chloro-3,4-methylenedioxyphenyl)methylthio)-1,3,4-Oxadiaz-
ole (6a) was sketched in Fig. 1. The 1H NMR spectrum indi-
cated four signals, for the 6-chloro-3,4-methylenedioxybenzyl
group attached at S-position of the 1,3,4-Oxadiazole group,
at d 7.09 (s, 1H, H-20) and 6.84 (s, 1H, H-50) for aromatic
protons and at d 5.94 (s, 2H, H-70) and 4.53 (s, 2H, H-80) for
aliphatic protons. The ﬁve protons of the phenyl group were
attributed by one doublet of doublet at d 7.98 (dd, J= 8.0,
1.2 Hz, 2H, H-200 & 600) and one multiplet in the range of
7.50–7.45 (m, 3H, H-300 to 500). The 13C NMR spectrum (BB
and DEPT) showed fourteen signals resonating for seven qua-
ternary, seven methylene and two methine carbons. The order
for seven signal quaternary carbons was d (ppm) 165.4 (C-5),164.6 (C-2), 150.3 (C-40), 148.7 (C-30), 129.8 (C-100), 129.5 (C-
10) and 125.7 (C-60). The seven methine carbons were nomi-
nated by ﬁve signals at d (ppm) 135.2 (C-300 & 500), 132.8 (C-
200 & 600), 130.4 (C-400), 110.9 (C-50) and 110.2 (C-20). The two
signals at d (ppm) 101.9 (C-70) and 32.7 (C-80) were assigned
to two methylene groups of benzodioxane moiety. All this
accumulative discussion, corroborated the structure of 6a as
5-phenyl-2-((6-chloro-3,4-methylenedioxyphenyl)methyl thio)-
1,3,4-Oxadiazole. The structures of other synthesized com-
pounds were conﬁrmed on the basis of spectral data, described
in experimental section.
3.2. Antibacterial activity (in vitro)
The %age inhibition (percentage inhibition) and MIC (mini-
mum inhibitory concentration) results of in vitro antibacterial
activity of the synthesized molecules against bacterial strains of
Gram-bacteria are depicted in Table 1 and Table 2,
respectively.
The screening of the synthesized series as 5-substituted-2-
((6-chloro-3,4-methylenedioxyphenyl)methylthio)-1,3,4-Oxadi-
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Figure 1 Mass fragmentation pattern of 5-phenyl-2-((6-chloro-3,4-methylenedioxyphenyl)methylthio)-1,3,4-Oxadiazole (6a).
Table 1 % age inhibition values of antibacterial activity.
Compound S. typhi () E. coli () P. aeroginosa () B. subtilis (+) S. aureus (+)
%age inhibition
6a 24.52 ± 4.52 64.44 ± 3.11 47.83 ± 4.33 38.85 ± 1.38 40.05 ± 0.14
6b 34.04 ± 1.35 56.67 ± 1.89 50.33 ± 3.25 48.85 ± 3.23 45.05 ± 0.95
6c 47.88 ± 2.98 62.94 ± 2.39 59.75 ± 3.83 53.35 ± 4.04 54.41 ± 0.68
6d 49.23 ± 4.81 53.44 ± 1.11 58.58 ± 1.33 55.15 ± 4.31 56.59 ± 5.00
6e 52.31 ± 3.65 64.83 ± 5.00 59.96 ± 0.21 41.12 ± 2.88 58.09 ± 2.09
6f 54.47 ± 4.47 72.28 ± 1.28 61.17 ± 4.25 58.04 ± 4.96 50.68 ± 0.23
6g 52.60 ± 0.00 61.33 ± 3.00 53.83 ± 1.58 61.31 ± 2.46 41.41 ± 0.86
6h 58.41 ± 4.57 70.33 ± 5.00 60.80 ± 4.79 56.54 ± 3.00 45.77 ± 1.23
6i 39.86 ± 1.39 57.94 ± 1.94 46.96 ± 0.13 40.54 ± 1.08 43.50 ± 3.50
6j 60.38 ± 4.33 74.11 ± 5.00 66.50 ± 2.25 58.46 ± 1.00 65.05 ± 3.86
6k 54.47 ± 3.99 57.67 ± 1.44 63.29 ± 0.46 53.73 ± 0.42 54.86 ± 2.05
6l 56.59 ± 1.88 70.94 ± 0.72 61.04 ± 0.21 54.04 ± 3.27 37.23 ± 3.32
Ciproﬂoxacin 90.76 ± 0.79 92.02 ± 1.97 90.32 ± 1.09 89.65 ± 2.00 91.22 ± 2.32
42 Aziz-ur-Rehman et al.azole against Gram-negative and Gram-positive bacteria
displayed that most of them executed moderate potential.
The molecules, 6f, 6j and 6k showed moderate activity against
all the bacterial strains. E. coli and P. aeroginosa (except 6a
and 6i) were inhibited by all the molecules of this series. A
few molecules remained inactive such as, 6c & 6d against
Salmonella typhi; 6e against Bacillus subtilis; and 6g, 6h & 6l
against Staphylococcus aureus. The most active molecule
among the whole series was 6j which exhibited good inhibitory
action against all the strains. The MIC values of this molecule
have been noted as 14.90 ± 2.41, 11.37 ± 4.23, 11.40 ± 2.88,
12.81 ± 2.44 and 13.68 ± 3.21 lM relative to ciproﬂoxacinwith MIC values of 8.33 ± 1.21, 8.94 ± 1.87, 8.14 ± 1.32,
9.04 ± 2.01 and 8.98 ± 1.44 lM. The prominent activity of
this molecule owes to the presence of the 4-chlorophenoxy
group in the molecule.4. Conclusion
The presented series of compounds was synthesized in good
yields to inaugurate some new antibacterial agents. Among
the synthesized molecules, all the molecules have exhibited
moderate activity against E. coli and the molecule, 6j, was
Table 2 MIC values of antibacterial activity.
MIC
Compound S. typhi () E. coli () P. aeroginosa () B. subtilis (+) S. aureus (+)
6a – 13.97 ± 3.85 – – –
6b – 16.17 ± 5.00 19.11 ± 1.30 – –
6c – 15.73 ± 1.54 14.90 ± 1.14 16.76 ± 3.38 17.75 ± 4.12
6d – 17.75 ± 3.08 12.52 ± 1.20 16.65 ± 1.23 15.84 ± 4.00
6e 18.03 ± 3.63 13.43 ± 5.00 15.01 ± 1.55 – 16.73 ± 3.13
6f 17.37 ± 1.87 11.73 ± 5.00 14.74 ± 4.35 17.02 ± 3.38 19.03 ± 2.98
6g 18.92 ± 4.12 14.51 ± 5.00 17.54 ± 3.45 15.54 ± 1.81 –
6h 15.00 ± 2.43 11.48 ± 2.46 15.08 ± 1.95 16.89 ± 3.50 –
6i – 14.87 ± 3.08 – – –
6j 14.90 ± 2.14 11.37 ± 4.23 11.40 ± 2.86 12.81 ± 2.44 13.68 ± 3.21
6k 17.28 ± 3.25 15.67 ± 3.00 15.56 ± 3.55 16.99 ± 4.19 17.59 ± 3.14
6l 16.27 ± 3.22 13.19 ± 3.31 14.51 ± 4.45 18.30 ± 1.25 –
Ciproﬂoxacin 8.33 ± 1.21 8.94 ± 1.87 8.14 ± 1.32 9.04 ± 2.01 8.98 ± 1.44
Note: Minimum inhibitory concentration (MIC) was measured with suitable dilutions (5–30 lg/ well) and results were calculated using EZ-Fit
Perrella Scientiﬁc Inc. Amherst USA software.
Synthesis of 1,3,4-oxadiazole derivatives as suitable antibacterial inhibitors 43the most active among this series. The synthesized molecules
might be helpful for the pharmaceutical industries in drug
discovery program.
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